Sanguine Corp. Inc. (OTCPK: SGUI) Announces Name Change to New Alliance BioSciences
Reflecting Their Broader Scope of Research and Development, Sanguine Corp. Inc. Obtains Shareholder Approval to Change Name to New Alliance BioSciences.
Atlanta, GA, June 24, 2015 --(PR.com)-- Sanguine Corp., Inc. (OTCPK: SGUI) announced today that it has obtained shareholder approval to change the name of the Company to New Alliance BioSciences. Frank Marra, President of the Company, made the following statement, “After careful consideration, and in order to better define our future, we have gotten shareholder approval to change our Company name to New Alliance BioSciences.” Mr. Marra added, “The world of oxygen therapeutics has progressed tremendously over the past five years and encompasses exponentially more indications other than just blood substitution and transfusions. We feel that the name Sanguine Corp. no longer reflects the broader scope of our research and development efforts.”
The Company will apply shortly for the new trading symbol “NABS” however, the final approval is at the discretion of the regulating authorities. Mr. Marra further added, “The Company will continue to trade under the call letters “SGUI” until further notification.”
If anyone has questions regarding the name change or any other information regarding this press release they are encouraged to contact Shane Shirley, Communications Director at (407) 230-8592.
About Sanguine Corp:
Sanguine Corporation is keenly focused on pioneering the development and commercialization of innovative perfluorocarbon-based therapies and medical devices. Its lead product, PHER-02, is an intravenous perfluorocarbon emulsion that is highly efficient at dissolving and delivering oxygen to tissues. Such properties make PHER-02 an ideal product for the treatment of a myriad of medical conditions with high morbidity and/or mortality directly resulting from a lack of oxygen at the cellular level. Sanguine’s philosophy is to develop products that have a sound scientific basis, a demonstrated proof of concept and adhere to the highest industry standards of product development.
For information related to the Sanguine Corp., contact Investor Relations: Shane Shirley at (407) 230-8592, email: shaneshirley@att.net.
Cautionary Note Regarding Forward-Looking Statements:
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
For Further Information Contact: Shane Shirley
(407) 230-8592
shaneshirley@att.net
The Company will apply shortly for the new trading symbol “NABS” however, the final approval is at the discretion of the regulating authorities. Mr. Marra further added, “The Company will continue to trade under the call letters “SGUI” until further notification.”
If anyone has questions regarding the name change or any other information regarding this press release they are encouraged to contact Shane Shirley, Communications Director at (407) 230-8592.
About Sanguine Corp:
Sanguine Corporation is keenly focused on pioneering the development and commercialization of innovative perfluorocarbon-based therapies and medical devices. Its lead product, PHER-02, is an intravenous perfluorocarbon emulsion that is highly efficient at dissolving and delivering oxygen to tissues. Such properties make PHER-02 an ideal product for the treatment of a myriad of medical conditions with high morbidity and/or mortality directly resulting from a lack of oxygen at the cellular level. Sanguine’s philosophy is to develop products that have a sound scientific basis, a demonstrated proof of concept and adhere to the highest industry standards of product development.
For information related to the Sanguine Corp., contact Investor Relations: Shane Shirley at (407) 230-8592, email: shaneshirley@att.net.
Cautionary Note Regarding Forward-Looking Statements:
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
For Further Information Contact: Shane Shirley
(407) 230-8592
shaneshirley@att.net
Contact
Shane Shirley
407.230.8592
407.230.8592
Contact
Categories